{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:20:56Z","timestamp":1758846056407,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:sec>\n                  <jats:title>Aims:<\/jats:title>\n                  <jats:p>To investigate the prognostic value of cyclin E in relation to tumour growth pattern by analysing stage II primary breast cancers from premenopausal women not subjected to any further adjuvant treatment. To analyse the value of cyclin E as a predictor of tamoxifen response, by comparing untreated and treated patients with oestrogen receptor positive tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Breast cancer samples, assembled in tissue microarrays, were immunohistochemically stained for cyclin E and evaluated regarding the presence of nuclear staining. The overall growth characteristics of each tumour were assessed using whole tissue sections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Tumours displaying a pushing margin phenotype were strongly associated with high cyclin E levels, lymph node negative disease, a high histological grade and oestrogen receptor negativity, and exhibited a better prognosis compared to tumours with an infiltrative growth pattern. In the total cohort of non-treated patients (n\u200a=\u200a187), cyclin E was not associated with recurrence free survival (RFS). However, when analysing the subgroup of tumours lacking a pushing growth pattern (n\u200a=\u200a141), cyclin E was significantly associated with RFS, independent of histological grade and node status. There was no significant difference in tamoxifen response with regard to different cyclin E levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>The prognostic value of cyclin E in premenopausal breast cancer is limited to patients with breast carcinomas exhibiting an exclusively infiltrative growth pattern. This limitation could be explained by the presence of a small but distinct subgroup of cyclin E-high breast cancers with a pushing margin phenotype and a more favourable outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp.2007.047688","type":"journal-article","created":{"date-parts":[[2007,5,4]],"date-time":"2007-05-04T21:09:50Z","timestamp":1178312990000},"page":"184-191","source":"Crossref","is-referenced-by-count":4,"title":["Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern"],"prefix":"10.1136","volume":"61","author":[{"given":"P","family":"Berglund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Stighall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fern\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Landberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2007,5,4]]},"reference":[{"key":"2025092509214464000_61.2.184.1","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/MCB.15.5.2612","article-title":"Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.","volume":"15","author":"Ohtsubo","year":"1995","journal-title":"Mol Cell Biol"},{"key":"2025092509214464000_61.2.184.2","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/MCB.15.7.3463","article-title":"Different roles for cyclins D1 and E in regulation of the G1-to-S transition.","volume":"15","author":"Resnitzky","year":"1995","journal-title":"Mol Cell Biol"},{"key":"2025092509214464000_61.2.184.3","doi-asserted-by":"publisher","DOI":"10.1038\/45836"},{"key":"2025092509214464000_61.2.184.4","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200404092"},{"key":"2025092509214464000_61.2.184.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3908"},{"key":"2025092509214464000_61.2.184.6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/MCB.17.1.453","article-title":"Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.","volume":"17","author":"Bortner","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2025092509214464000_61.2.184.7","first-page":"380","article-title":"Cyclin E, a potential prognostic marker for breast cancer.","volume":"54","author":"Keyomarsi","year":"1994","journal-title":"Cancer Res"},{"key":"2025092509214464000_61.2.184.8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.451"},{"key":"2025092509214464000_61.2.184.9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1155\/1998\/659712","article-title":"Cyclin E expression and proliferation in breast cancer.","volume":"17","author":"Nielsen","year":"1998","journal-title":"Anal Cell Pathol"},{"key":"2025092509214464000_61.2.184.10","doi-asserted-by":"publisher","DOI":"10.1038\/nm0297-222"},{"key":"2025092509214464000_61.2.184.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0225"},{"key":"2025092509214464000_61.2.184.12","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.21141"},{"key":"2025092509214464000_61.2.184.13","doi-asserted-by":"publisher","DOI":"10.1002\/path.1322"},{"key":"2025092509214464000_61.2.184.14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj467"},{"key":"2025092509214464000_61.2.184.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3984"},{"key":"2025092509214464000_61.2.184.16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800255"},{"key":"2025092509214464000_61.2.184.17","first-page":"1","article-title":"Medullary carcinoma of the breast.","volume":"75","author":"Pedersen","year":"1997","journal-title":"APMIS Suppl"},{"key":"2025092509214464000_61.2.184.18","first-page":"71","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists\u2019 Collaborative Group.","volume":"339","author":"EBCTGC","year":"1992","journal-title":"Lancet"},{"key":"2025092509214464000_61.2.184.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"2025092509214464000_61.2.184.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc721"},{"key":"2025092509214464000_61.2.184.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81879-6"},{"key":"2025092509214464000_61.2.184.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.10.5382"},{"key":"2025092509214464000_61.2.184.23","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.23.8667-8675.2000"},{"key":"2025092509214464000_61.2.184.24","first-page":"511S","article-title":"ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.","volume":"9","author":"Kurokawa","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025092509214464000_61.2.184.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205576"},{"key":"2025092509214464000_61.2.184.26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3672"},{"key":"2025092509214464000_61.2.184.27","first-page":"6916","article-title":"Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.","volume":"62","author":"Hui","year":"2002","journal-title":"Cancer Res"},{"key":"2025092509214464000_61.2.184.28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206818"},{"key":"2025092509214464000_61.2.184.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.030"},{"key":"2025092509214464000_61.2.184.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021153"},{"key":"2025092509214464000_61.2.184.31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11132"},{"key":"2025092509214464000_61.2.184.32","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N"},{"key":"2025092509214464000_61.2.184.33","doi-asserted-by":"publisher","DOI":"10.1002\/path.1845"},{"key":"2025092509214464000_61.2.184.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0031"},{"key":"2025092509214464000_61.2.184.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2007.047688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:21:52Z","timestamp":1758817312000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2007.047688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,4]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,1,25]]},"published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1136\/jcp.2007.047688"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2007.047688","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2007,5,4]]}}}